U.S. uses implantable devices to treat high blood pressure

In the United States, with the increase in obesity, the incidence of hypertension has also increased significantly in recent years. The traditional treatment of hypertension has been dominated by drugs. The US medical device company CVRx is committed to the treatment of hypertension from implantable devices. And the heart failure disorder caused by it.

On August 9, CVRx announced the completion of the $113 million Series G round of financing, including $93 million in equity financing and $20 million in debt financing. This round of financing was led by Johnson & Johnson Innovation–JJDC, including New Enterprise Associates, Ysios BioFund I FCR and Windham Venture Partners. The company plans to use this round of financing to complete clinical trials of heart failure baroreceptor reflex stimulation (BeAT-HF) and expand the company's global business.

Founded in 2001 and headquartered in Minnesota, CVRx is a privately held company dedicated to the development of implantable technologies. The company developed the second generation of minimally invasive implant system BAROSTIM NEO, which was granted the US Food and Drug Administration's humanitarian device exemption. The device is implanted subcutaneously near the human clavicle to stimulate the human nerve reflex system to help control blood flow. In general, neuromodulation techniques are mainly used to treat pain symptoms, and CRVx is applied to antihypertensive and heart failure through innovative means.

Heart failure is mainly manifested in the inability of the heart to pump enough blood to supply the vitality and metabolism of various organs of the body. The baroreceptor reflex ability is lost and the blood flow cannot be properly regulated. BAROSTIM NEO regulates the baroreceptors of the carotid wall and activates baroreflex through the afferent pathway of the autonomic nervous system. The brain then regulates the efferent pathway, relaxes the blood vessels and slows the heart rate, ultimately achieving a blood pressure lowering effect.

The product has received European CE certification for medical devices in the treatment of heart failure and refractory hypertension and is currently undergoing clinical evaluations in the United States and Canada. In addition, it has potential effects in the treatment of chronic kidney disease.